Bioventus Inc. (NASDAQ:BVS) Q4 2022 Earnings Call Transcript

Unidentified Analyst: Hi, this is (ph) on for Drew. Thanks for taking the questions. And for 2023, I was wondering if there’s anything you could give us on cadence through the year either on revenue or margins. Should we be thinking about seasonality similar to historical with the exception of Pain Treatments given the pricing headwind there?

Mark Singleton: Yes. This is Mark. I’d say that we don’t expect to have a lot different kind of revenue phasing, throughout the year wouldn’t be a lot different than we’ve historically had. We don’t expect any big spikes or troughs.

Unidentified Analyst: Great, thanks. And then for gross margin, should we be thinking about maybe low 70 as the right run rate going forward? Or maybe any color on the moving parts for gross margin into €˜23 would be helpful.

Mark Singleton: Yes. Well, I’m not going to get into a comment on that since we’re not providing guidance, but wouldn’t expect it to be significantly different than what we’ve seen coming out of the fourth quarter.

Unidentified Analyst: Great. Thank you.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to CEO, Ken Reali for any closing remarks.

Ken Reali: Well, thanks, everyone, for your continued interest in Bioventus. While near-term challenges remain in our business, we are confident in the revenue and earnings growth opportunities as we move through 2023. We participate in large growing markets and provide innovative differentiated products to our patients. Most importantly, we have a dedicated team of employees that are focused on our mission and stakeholder value creation. In the coming quarters, we look to regain your confidence in our ability to execute and deliver on our commitments as we begin to improve our growth and margin profile to create stakeholder value. Thank you very much.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.